enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Disease-modifying osteoarthritis drug - Wikipedia

    en.wikipedia.org/wiki/Disease-modifying...

    A disease-modifying osteoarthritis drug (DMOAD) is a disease-modifying drug that would inhibit or even reverse the progression of osteoarthritis. [1] Since the main hallmark of osteoarthritis is cartilage loss, a typical DMOAD would prevent the loss of cartilage and potentially regenerate it.

  3. Regenerative medicine advanced therapy - Wikipedia

    en.wikipedia.org/wiki/Regenerative_Medicine...

    Regenerative Medicine Advanced Therapy (RMAT) is a designation given by the Food and Drug Administration to drug candidates intended to treat serious or life-threatening conditions under the 21st Century Cures Act. [1] A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints. [2]

  4. Mavrilimumab - Wikipedia

    en.wikipedia.org/wiki/Mavrilimumab

    Mavrilimumab is a human monoclonal antibody [1] that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R). [2]Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc. [1] as an investigational drug for the treatment of rheumatoid arthritis

  5. FDA Approves Expanded Indication for ACTEMRA® in ... - AOL

    www.aol.com/2012/10/12/fda-approves-expanded...

    FDA Approves Expanded Indication for ACTEMRA ® in Rheumatoid Arthritis SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY ...

  6. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in people unable to tolerate UDCA [2] Epkinly: Treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy [2] Fidanacogene ...

  7. FDA Approves AbbVie's JAK Inhibitor Application For Active ...

    www.aol.com/news/fda-approves-abbvies-jak...

    The FDA approved AbbVie Inc's (NYSE: ABBV) Rinvoq (upadacitinib; 15 mg) for active psoriatic arthritis (PsA). Like Pfizer Inc's (NYSE: PFE) approval for Xeljanz, Rinvoq's approval also covers ...

  8. Will Antares' FDA Decision Mean Good News for Arthritis ... - AOL

    www.aol.com/news/2013-10-14-will-antares-fda...

    Antares Pharma on Monday received the news it hoped to get. The Food and Drug Administration gave a thumbs-up to Otrexup, the company's subcutaneous methotrexate administered via self-injection.

  9. Adalimumab - Wikipedia

    en.wikipedia.org/wiki/Adalimumab

    Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.